DDAH: a target for vascular therapy?
作者信息
Cooke John P
出版信息
Vasc Med. 2010 Jun;15(3):235-8. doi: 10.1177/1358863X10362605. Epub 2010 Apr 12.
Abstract
摘要
相似文献
1
DDAH: a target for vascular therapy?
Vasc Med. 2010 Jun;15(3):235-8. doi: 10.1177/1358863X10362605. Epub 2010 Apr 12.
2
Adenoviral-mediated overexpression of DDAH improves vascular tone regulation.
Vasc Med. 2010 Jun;15(3):205-13. doi: 10.1177/1358863X09360264. Epub 2010 Mar 10.
3
S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase.
Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13527-32. doi: 10.1073/pnas.212269799. Epub 2002 Oct 7.
4
DDAH-2 alleviates contrast medium iopromide-induced acute kidney injury through nitric oxide synthase.
Clin Sci (Lond). 2019 Dec 12;133(23):2361-2378. doi: 10.1042/CS20190455.
5
Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase.
Circ Res. 2003 Feb 7;92(2):226-33. doi: 10.1161/01.res.0000052990.68216.ef.
6
DDAH says NO to ADMA.
Arterioscler Thromb Vasc Biol. 2011 Jul;31(7):1462-4. doi: 10.1161/ATVBAHA.111.228833.
7
Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems.
Am J Physiol Heart Circ Physiol. 2007 Dec;293(6):H3227-45. doi: 10.1152/ajpheart.00998.2007. Epub 2007 Oct 12.
8
The DDAH/ADMA/NOS pathway.
Atheroscler Suppl. 2003 Dec;4(4):33-40. doi: 10.1016/s1567-5688(03)00032-1.
9
Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.
Eur J Pharmacol. 2008 Apr 14;584(1):49-56. doi: 10.1016/j.ejphar.2008.01.029. Epub 2008 Feb 5.
10
all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase.
Circ Res. 2002 Apr 19;90(7):764-9. doi: 10.1161/01.res.0000014450.40853.2b.
引用本文的文献
1
Short-term usage of proton pump inhibitors during admission was associated with increased risk of rehospitalization in critically ill patients with myocardial infarction: a cohort study.
Eur J Clin Pharmacol. 2024 Nov;80(11):1741-1750. doi: 10.1007/s00228-024-03737-y. Epub 2024 Aug 14.
2
Proton Pump Inhibitor Use and the Risk of Cardiovascular Complications and Death in Older Adults with Diabetes: A Population-Based Cohort Study.
Drugs Aging. 2024 Mar;41(3):239-249. doi: 10.1007/s40266-024-01097-x. Epub 2024 Feb 17.
3
Pyrrolidine dithiocarbamate ameliorates endothelial dysfunction in thoracic aorta of diabetic rats by preserving vascular DDAH activity.
PLoS One. 2017 Jul 17;12(7):e0179908. doi: 10.1371/journal.pone.0179908. eCollection 2017.
4
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population.
PLoS One. 2015 Jun 10;10(6):e0124653. doi: 10.1371/journal.pone.0124653. eCollection 2015.
5
Intermittent claudication: new targets for drug development.
Drugs. 2013 Jul;73(10):999-1014. doi: 10.1007/s40265-013-0078-3.
6
FXR agonist INT-747 upregulates DDAH expression and enhances insulin sensitivity in high-salt fed Dahl rats.
PLoS One. 2013 Apr 4;8(4):e60653. doi: 10.1371/journal.pone.0060653. Print 2013.
7
Nitric oxide manipulation: a therapeutic target for peripheral arterial disease?
Cardiol Res Pract. 2012;2012:656247. doi: 10.1155/2012/656247. Epub 2012 Mar 20.
本文引用的文献
1
Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.
J Biol Chem. 2009 Dec 18;284(51):35338-47. doi: 10.1074/jbc.M109.037036.
2
Developing dual and specific inhibitors of dimethylarginine dimethylaminohydrolase-1 and nitric oxide synthase: toward a targeted polypharmacology to control nitric oxide.
Biochemistry. 2009 Sep 15;48(36):8624-35. doi: 10.1021/bi9007098.
3
Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community.
Circulation. 2009 Mar 31;119(12):1592-600. doi: 10.1161/CIRCULATIONAHA.108.838268. Epub 2009 Mar 16.
4
Asymmetric dimethylarginine: a novel marker of risk and a potential target for therapy in chronic kidney disease.
Curr Opin Nephrol Hypertens. 2008 Nov;17(6):609-15. doi: 10.1097/MNH.0b013e328314b6ca.
5
Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart.
Science. 2008 Sep 12;321(5895):1493-5. doi: 10.1126/science.1158554.
6
L-arginine supplementation in peripheral arterial disease: no benefit and possible harm.
Circulation. 2007 Jul 10;116(2):188-95. doi: 10.1161/CIRCULATIONAHA.106.683656. Epub 2007 Jun 25.
7
Disruption of methylarginine metabolism impairs vascular homeostasis.
Nat Med. 2007 Feb;13(2):198-203. doi: 10.1038/nm1543. Epub 2007 Feb 4.
8
ADMA metabolism and clearance.
Vasc Med. 2005 Jul;10 Suppl 1:S73-81. doi: 10.1191/1358863x05vm597oa.
9
Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis.
Circulation. 2005 Mar 22;111(11):1431-8. doi: 10.1161/01.CIR.0000158487.80483.09.
10
Asymmetrical dimethylarginine: the Uber marker?
Circulation. 2004 Apr 20;109(15):1813-8. doi: 10.1161/01.CIR.0000126823.07732.D5.
Zotero 插件